Overview of Lercapril

Property	Description
Active ingredient	Enalapril maleate, Lercanidipine hydrochloride
Form	Film-coated tablet
Pharmacological class	Antihypertensive (Fixed-Dose Combination)
Type	Prescription-only medicine
Origin	Synthetic compound

What Type of Medicine is Lercapril? (Identity and Classification)

Lercapril is a synthetic, prescription-only medication, formally classified as a Fixed-Dose Combination (FDC) Antihypertensive Agent. The medication is clinically utilized for its role in managing hypertension. The product is engineered to deliver two active compounds simultaneously within a single film-coated tablet designed for oral use. FDC therapies are a recognized strategy in clinical management to potentially improve patient adherence by simplifying complex treatment regimens.

Composition: Enalapril and Lercanidipine

The core of Lercapril is its dual composition, comprising Enalapril maleate and Lercanidipine hydrochloride. Enalapril maleate is an Angiotensin-Converting Enzyme (ACE) inhibitor, a class of drug that acts as a prodrug and is involved in regulating systemic vascular resistance. Lercanidipine hydrochloride, conversely, belongs to the Dihydropyridine Calcium Channel Blocker (CCB) class. Both active substances are synthetically derived. The specific pairing of Enalapril, a long-established ACE inhibitor, with Lercanidipine, a CCB known for its particular pharmacokinetic profile, represents a common pairing in cardiovascular medicine.

General Purpose of the Dual-Component Approach

The foundational purpose of Lercapril is to provide a comprehensive, two-pronged strategy for achieving and sustaining effective blood pressure control, typically when a patient's condition is not adequately managed by either component alone. The combination of an ACE inhibitor and a CCB is pharmacologically favored as the two classes produce a synergistic vasodilation effect. This synergistic approach aims to offer control over the circulatory system through the combined action of both agents, forming a therapeutic basis for the treatment.

What side effects are possible with Lercapril?

Possible Side Effects and Safety Information

Lercapril is a fixed-dose combination of enalapril (an ACE inhibitor) and lercanidipine (a calcium channel blocker). The safety profile is characterized by the adverse reactions associated with both components, which are categorized by frequency based on regulatory standards (e.g., CIOMS III/ICH frequency bands).

Adverse Reactions and Frequencies

Common adverse reactions (may affect up to 1 in 10 people) generally include effects on the nervous and cardiovascular systems, such as dizziness and headache. Uncommon reactions (may affect up to 1 in 100 people) can involve metabolic or cardiac issues, including hyperkalaemia, tachycardia, and palpitations. Rare events (may affect up to 1 in 1,000 people) include hypersensitivity reactions.

Serious and Clinically Significant Risks

Serious adverse reactions reported with ACE inhibitors, like enalapril, include angioedema (swelling of the face, limbs, lips, tongue, glottis, and/or larynx), which can occur at any time during treatment and requires immediate medical attention. Renal failure is a significant risk, particularly in patients with severe underlying heart failure or renovascular hypertension. Increased frequency, duration, or severity of angina pectoris has been rarely observed upon initiating or increasing the dose of lercanidipine.

Safety Restrictions and Limitations

Lercapril is contraindicated in patients with a history of angioedema related to previous ACE inhibitor use, and in those with severe renal dysfunction (creatinine clearance <30 ml/min) or undergoing dialysis. It is also contraindicated in severe hepatic dysfunction. Treatment must be discontinued upon confirmed or suspected pregnancy as the drug is known to cause harm to a developing fetus, and it is also contraindicated during lactation. Due to increased exposure risks, concomitant use with grapefruit or grapefruit juice and ciclosporin is prohibited. Caution is required in patients with ischaemic heart disease or left ventricular outflow obstruction.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Lercapril, a fixed-dose combination, is documented based on the severe physiological consequences of excessive antihypertensive action. Overdose is primarily associated with a profound drop in blood pressure.

Documented Overdose Manifestations	When Immediate Medical Help Is Required
Severe Hypotension (excessive blood pressure reduction)	Seek Immediate Medical Attention or Call Emergency Services if overdose is suspected.
Bradycardia or Reflex Tachycardia	Go to the Hospital Straight Away for manifestations such as loss of consciousness or severe cardiovascular signs.
Dizziness, Fainting (Syncope), and Unconsciousness	Airway obstruction due to laryngeal angioedema requires emergency intervention.

The primary documented risk is the potential for Life-Threatening Systemic Complications, including Myocardial Infarction or Cerebrovascular Accident secondary to sustained, severe hypotension.

Management and Constraints:

No specific antidote is known for the Lercanidipine component of the combination.
Treatment mandated by regulatory documents is Symptomatic and Supportive, including Monitoring Blood Pressure and Heart Function.
Prolonged Observation in a high-care setting may be required in cases of moderate to severe intoxication.

This structure emphasizes the regulatory mandate that any suspected overdose must trigger immediate emergency medical care, focusing on documented severe cardiovascular risks and the need for supportive procedures.

Therapeutic Uses of Lercapril

What Lercapril Treats: Main Uses and Benefits

The therapeutic application of Lercapril generally plays a role in managing chronic high blood pressure. The core therapeutic domain for this combination is for the management of essential hypertension in adults.

Clinical Focus and Patient Benefit

This medication is applied in conditions characterized by periods of heightened symptoms where the patient's blood pressure remains uncontrolled when taking only a single therapeutic agent, such as Enalapril or Lercanidipine alone. It is commonly used when patients may require an alternative dual-acting approach to help manage persistently high arterial pressure readings.

The key indications addressed include easing manifestations of uncontrolled essential hypertension, the management of increased cardiovascular risk, and situations relevant for supporting patient adherence. In relevant clinical contexts, the medicine contributes to easing organ-specific functional stress and may assist with managing symptoms associated with chronic high pressure.

“This fixed-dose approach supports the patient in maintaining a consistent routine, which is important when managing chronic conditions where stability becomes affected.”

This support helps ease the overall symptom burden and contributes to improved day-to-day comfort during symptomatic periods.

Supportive Use: Management of Pathological Vascular Tension

The medication is commonly used to help manage the symptoms related to systemic imbalance, which is a key factor in conditions where functional stability becomes affected. It provides supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Lercapril is intended solely for adults (age 18 and older) who require treatment for essential hypertension and whose condition is not adequately controlled with Lercanidipine monotherapy. Use in the pediatric population is not established and is therefore not recommended by regulatory authorities.

Population Status	Condition or Limitation
Absolute Contraindication	Hypersensitivity to enalapril, lercanidipine, or any ACE inhibitor/dihydropyridine calcium channel blocker.
Absolute Contraindication	History of angioedema related to prior ACE inhibitor use, or hereditary/idiopathic angioedema.
Absolute Contraindication	Severe hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min), including patients undergoing dialysis.
Absolute Contraindication	Specific heart conditions, including untreated congestive heart failure, unstable angina, or recent myocardial infarction (within one month).
Absolute Contraindication	Second and third trimesters of pregnancy and during lactation (breastfeeding).
Restriction: Caution Needed	Mild to moderate renal or hepatic impairment.
Restriction: Caution Needed	First trimester of pregnancy (use not recommended).

The official labeling prohibits use in those with severe organ dysfunction and various acute cardiovascular instabilities. Additionally, the medicine must not be used concurrently with sacubitril/valsartan or with aliskiren-containing products in patients with diabetes or renal impairment. This structured regulatory profile formally defines the necessary exclusions for use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interaction patterns for Lercapril, a fixed-dose combination of Enalapril maleate and Lercanidipine hydrochloride, as defined in government regulatory labeling.

Contraindicated Combinations

Co-administration with several substances is formally prohibited in regulatory documents due to increased risk. This includes Sacubitril/valsartan, where the Enalapril component requires a 36-hour separation period. Aliskiren-containing products are contraindicated in patients with diabetic or moderate-to-severe renal impairment. Strong inhibitors of the CYP3A4 metabolic enzyme, such as Ketoconazole and Ritonavir, are prohibited as they significantly increase Lercanidipine's systemic exposure. The ingestion of Grapefruit or grapefruit juice is also formally contraindicated for the same reason.

Pharmacodynamic and Metabolic Interactions

Interactions often involve the additive effects of the two components. Co-administration with potassium-sparing diuretics (e.g., Spironolactone) or potassium supplements increases the risk of hyperkalaemia. Concurrent use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the antihypertensive effect and potentially impair renal function. The label also documents that Lercapril must be administered at least 15 minutes before breakfast, and alcohol should be avoided as it potentiates the vasodilating effects.

Mechanism of Action

Blocking Calcium Channels in Artery Walls

Lercapril acts as a selective inhibitor of the L-type voltage-gated calcium channels ( Cav1.2) found on the surface of vascular smooth muscle cells . By binding to and physically blocking these channels, the molecule prevents the influx of extracellular calcium ions ( Ca^2+) into the cells. This molecular action disrupts the Ca^2+-dependent signal required for smooth muscle contraction.

Reducing Systemic Vascular Resistance

This molecular blockade directly interrupts the excitation-contraction coupling pathway within the arterial walls, causing the arterial smooth muscle to relax and leading to widespread vasodilation (widening of the arteries). The resulting physiological consequence is a reduction in the Systemic Vascular Resistance (SVR), which is the resistance to blood flow within the systemic circulation.

Selectivity for Peripheral Vasculature

Lercapril's mechanism exhibits functional vasoselectivity because its inhibitory action is strongest on channels that are frequently activated or depolarized, primarily those located in the peripheral arteries. This means the mechanism preferentially regulates peripheral vessel tension, rather than mechanisms predominantly governing cardiac contractility, which contributes to the observed reduction in systemic resistance.

Dosage and Administration Information

How to Use Lercapril: Official Administration Guidelines

The use of Lercapril is governed by standardized instructions that define the established method for taking the medication.

Administration Scope

Feature	Instruction
Route of administration	The medicine is taken for oral use as a film-coated tablet.
Dosing schedule	The standard recommended dose is one tablet once daily. This fixed-dose combination (FDC) is not for initial treatment of hypertension; it is used when blood pressure remains uncontrolled on monotherapy with one of its components.
Timing in relation to meals	Must be administered at least 15 minutes before any meal, preferably before breakfast.
Preparation requirements	The tablet should be swallowed whole with a sufficient amount of fluid.
Age-group administration rules	For elderly patients, the dose must be determined based on the patient's renal function. The FDC is not recommended for the pediatric population due to insufficient data.
Special procedural conditions	The medicine is contraindicated in severe renal impairment (creatinine clearance <30 mL/ min). Consumption of grapefruit or grapefruit juice and alcohol must be strictly avoided during treatment.

Instruction Classifications

Classification	Detail
Administration method type	Oral
Frequency pattern	Daily
Use-context constraints	Used for maintenance only; requires prior history of uncontrolled blood pressure on monotherapy.

Resulting Procedural Structure

The formal use protocol requires the tablet to be administered once daily in the morning, separated from food intake by a minimum of 15 minutes, and explicitly prohibits the consumption of alcohol or grapefruit products.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lercapril

The research evidence for Lercapril focuses on its Fixed-Dose Combination (FDC), which was studied for high blood pressure. Clinical evaluation primarily involved controlled trials examining the combination of two active substances.

Research Evidence for Managing Essential Hypertension

The main body of research was evaluated in Randomized Controlled Trials (RCTs) examining essential hypertension in adults. Research focused on individuals whose blood pressure levels were measured as not adequately controlled on monotherapy. Studies monitored primary outcomes measuring blood pressure and found differences in blood pressure readings when compared to the individual components administered alone. This evidence contributes to understanding short-term changes observed in patient groups.

Study Designs and Outcomes Examined

The studies evaluated the FDC through short-term trials designed to measure the percentage of people who achieved specific blood pressure control rates. Research also examined outcomes using 24-hour Ambulatory Blood Pressure Monitoring (ABPM). Findings indicate that patterns measured during the study period were observed in some studies consistently across both in-office and out-of-office settings.

Evidence in Specific Patient Populations

The research included specific subgroups, such as older adults (60–85 years) and patients with type 2 diabetes co-occurring with hypertension. These trials often monitored not only blood pressure but also that research examined certain metabolic parameters. Research does not determine whether an individual will respond similarly, and results apply only to the populations studied.

Long-Term Studies and Durability of Response

Most pivotal trials had follow-up durations that were limited, typically 10 to 12 weeks. This design provides data on short-term symptom patterns but does not fully characterize the durability of the measured blood pressure pattern over many years.

Evidence Gaps and Areas for Future Research

A key limitation is that primary endpoints were surrogate markers (blood pressure reduction) rather than major long-term effects on morbidity and mortality (M/M) outcomes. Consequently, the long-term impact on M/M outcomes is not yet clear whether it can be fully established. Data for certain groups also remain insufficient to draw broad conclusions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lercapril (FAQ)

Q: Does Lercapril start working immediately?

A: This medication is intended for maintenance treatment of high blood pressure. Official information suggests that the maximal blood pressure lowering effect of the lercanidipine component may be fully apparent after approximately two weeks.

Q: How long does it usually take to see the full effect of Lercapril?

A: The full, intended blood pressure-lowering pattern may take time to stabilize. Dose adjustment is typically gradual because official information notes it may take up to about two weeks for the maximal antihypertensive effect to be observed.

Q: Does Lercapril interact with pain relievers like ibuprofen?

A: Official product information documents an interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a class that includes ibuprofen. Concurrent use may potentially reduce the medicine's effectiveness in lowering blood pressure and could affect kidney function. Patients are advised to inform a healthcare provider of all current medications and supplements.

Q: Can Lercapril affect your kidneys?

A: Severe kidney impairment (creatinine clearance less than 30 mL/min) is a contraindication for use. Official warnings report that renal failure has been documented in association with the enalapril component, primarily in patients with pre-existing heart or renal conditions.

Q: Is it common to feel dizzy when starting Lercapril?

A: Dizziness is listed in the official documents as a common adverse reaction, meaning it may affect up to 1 in 10 people. Caution is advised regarding tasks requiring full attention, such as driving or operating machinery, particularly when initiating treatment.

Q: Is it okay to take Lercapril at night or in the morning?

A: The medicine is described in official documents as being administered once daily. Official product documents specify that it should be taken preferably before breakfast, and always at least 15 minutes before any meal.

Q: How often are blood tests needed when taking Lercapril?

A: Official documents advise that periodic monitoring of blood components and electrolytes (like potassium) should be performed. Monitoring is advised for certain high-risk patient groups, such as those with impaired kidney or heart function.

Q: Do official documents mention any connection between Lercapril and depression?

A: Official documentation for the enalapril component, which is one of the two active substances, lists depression as a common psychiatric adverse reaction. Other psychiatric effects that have been reported include confusion and difficulty sleeping.

Q: What are the signs of a severe allergic reaction to Lercapril?

A: A serious reaction that has been reported is angioedema, which involves swelling of the face, extremities, lips, tongue, or throat. Other signs of hypersensitivity reactions may include itching or rash, which are listed in the official safety information.

Q: What happens if you stop taking Lercapril suddenly?

A: Official guidance indicates that abrupt discontinuation of antihypertensive therapy may be associated with an increase in blood pressure. Any changes to treatment should be discussed with a qualified professional.

Q: Is there a list of foods or drinks to avoid while on Lercapril?

A: The official label specifies that consumption of grapefruit or grapefruit juice is formally contraindicated. Furthermore, alcohol should be avoided as official information notes it may increase the medicine's vasodilating (artery-widening) effect.

Q: Can Lercapril be taken with vitamins or minerals?

A: While regulatory labels do not list every vitamin, the official label notes that ACE inhibitors can increase potassium levels. Due to the potential for increased potassium (hyperkalaemia), official documents advise caution regarding the use of potassium supplements.

Q: Is Lercapril safe for older adults?

A: Official documents indicate that the medicine can be used in older adults, but that special care is advised when starting treatment. The dose should be determined based on the assessment of the patient's kidney function.

Q: Can Lercapril affect sleep?

A: The official documentation for the enalapril component lists insomnia (difficulty falling or staying asleep) and sleep disorders as uncommon or rare adverse reactions, respectively.

Q: Can Lercapril cause dry mouth?

A: Official documentation for the enalapril component lists dry mouth as an uncommon adverse reaction within the gastrointestinal category.

Q: Does Lercapril affect blood sugar levels?

A: Studies on the lercanidipine component suggest it does not appear to negatively influence blood sugar levels. Furthermore, research on the enalapril component in patients with diabetes has suggested certain effects related to metabolic parameters, including insulin sensitivity.

Q: Is it safe to drive while taking Lercapril?

A: Official information advises caution regarding tasks requiring full attention, such as driving or using machinery, due to the potential for common adverse effects like dizziness, fatigue, and somnolence (drowsiness).

Q: Why is Lercapril sometimes prescribed along with a diuretic?

A: Combination therapy with a diuretic is a known strategy in the management of high blood pressure. Official regulatory information notes that combining the agents may increase the risk of hypotension when starting treatment.

Q: Is sun sensitivity a concern while taking Lercapril?

A: Official documentation for the enalapril component notes that a complex of symptoms may occur which includes photosensitivity (increased sensitivity to sunlight) as a potential skin reaction.

Q: Can Lercapril cause stomach upset?

A: Yes, official documentation for the enalapril component lists several gastrointestinal adverse reactions. These include abdominal pain, nausea, and diarrhea as common or uncommon reactions.

Q: Does Lercapril help protect the heart?

A: The medicine is indicated for lowering blood pressure. While blood pressure reduction is beneficial, the research evidence is limited on the long-term impact of this specific fixed-dose combination on major outcomes. The enalapril component is, however, recognized for its renoprotective properties (actions that help protect the kidneys).

Q: Can Lercapril be used for anxiety-related blood pressure spikes?

A: The medicine is formally indicated only for the treatment of essential hypertension (high blood pressure of unknown cause). It is not indicated for treating acute, temporary blood pressure increases that may be related to anxiety.

Q: Do older adults experience side effects differently when taking Lercapril?

A: While research includes older patients, clinical literature notes that simplifying therapy with a fixed-dose combination may reduce the incidence of certain side effects, such as peripheral edema (swelling of the ankles/legs), compared to taking a higher dose of the calcium channel blocker component alone.

Q: Can Lercapril cause a cough?

A: The enalapril component of the medicine is associated with a cough. Regulatory documents list this effect as a very common adverse reaction, meaning it has been observed to affect more than 1 in 10 people.

How should Lercapril be stored and disposed of?

Storage and Disposal of Lercapril

Lercapril (Enalapril maleate/Lercanidipine hydrochloride) must be stored and handled according to specific conditions detailed in the official regulatory labeling to ensure its stability.

Required Storage Conditions

Condition	Requirement
Temperature	Do not store above 25^circC (or 30^circC depending on regional labeling).
Protection	Must be stored in the original package to protect from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.

Official Disposal Instructions

Regulatory documents provide explicit guidance on disposal to protect the environment. Unused or expired Lercapril must not be thrown away via wastewater or household waste. The official procedure requires consulting a pharmacist for instructions on how to properly discard the medicine.

Lercapril